Relapsed/Refractory Acute Myeloid Leukemia Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

 Breaking News
  • No posts were found

Relapsed/Refractory Acute Myeloid Leukemia Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

Relapsed/Refractory Acute Myeloid Leukemia Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Relapsed/refractory acute myeloid leukemia (AML) Pipeline Insight 2024” report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the Relapsed/Refractory Acute Myeloid Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Relapsed/Refractory Acute Myeloid Leukemia Research. Learn more about our innovative pipeline today! @ Relapsed/Refractory Acute Myeloid Leukemia Pipeline Outlook

Key Takeaways from the Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report

  • June 2024:- Ryvu Therapeutics SA- A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of RVU120 in Combination With Venetoclax in Participants With Acute Myeloid Leukemia Who Failed Prior Therapy With Ventoclax and a Hypomethylating Agent.
  • June 2024:- LLS PedAL Initiative LLC- A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin [GO]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are unable to receive additional anthracyclines, or in 2nd relapse.
  • DelveInsight’s Relapsed/Refractory Acute Myeloid Leukemia pipeline report depicts a robust space with 50+ active players working to develop 75+ pipeline therapies for Relapsed/Refractory Acute Myeloid Leukemia treatment.
  • The leading Relapsed/Refractory Acute Myeloid Leukemia Companies such as Ascentage Pharma, Cullinan Oncology, Kronos Bio, Maxinovel Pharmaceuticals, AB Science, CicloMed, Karyopharm Therapeutics, Antengene Corporation, GlycoMimetics, Servier, Novartis, ImmunoGen, and others.
  • Promising Relapsed/Refractory Acute Myeloid Leukemia Therapies such as UCART 123, FHD-286, AB8939, ONC201, Sarclisa, TCB008, Keytruda, Uproleselan, Crenolanib, and others.

Stay informed about the cutting-edge advancements in Relapsed/Refractory Acute Myeloid Leukemia Treatments. Download for updates and be a part of the revolution in oncology care @ Relapsed/Refractory Acute Myeloid Leukemia Clinical Trials Assessment

Relapsed/Refractory Acute Myeloid Leukemia Emerging Drugs Profile

  • APG-2575: Ascentage Pharma

APG-2575 is a novel oral Bcl-2 selective small molecule inhibitor under development by Ascentage Pharma. It restores the programmed cell death mechanism (apoptosis) of tumor cells by selectively inhibiting Bcl-2 protein, thereby inducing tumor cell apoptosis. , to achieve the purpose of tumor treatment. APG-2575 is the first locally developed Bcl-2 selective inhibitor to enter clinical stage in China. APG-2575 has been granted orphan drug designation by the US FDA for five indications (Indications: refractory chronic lymphocytic leukemia CLL, multiple myeloma, Waldenström macroglobulinemia, acute myeloid leukemia, follicular lymphoma).

  • CLN 049: Cullinan Oncology

CLN-049 (Florentine) is a humanized bispecific T cell engaging antibody being developed for the treatment of acute myeloid leukemia (AML). CLN-049 is designed to simultaneously bind to FLT3 on targeted leukemic cells and to CD3 on T cells, triggering the T cells to kill the selected cancer cells via their intrinsic cytolytic mechanisms. FLT3 is expressed frequently on AML cells and leukemic blasts but minimally on healthy blood cells, unlike other tumor surface antigens identified in AML, such as CD33 and CD123. CLN-049 can mediate potent and specific lysis of AML cells in vitro and promotes enhanced survival of mice bearing AML tumors. A phase I clinical trial with CLN-049 is currently ongoing for the treatment of patients with relapsed/refractory AML or MDS.

  • Lanraplenib: Kronos Bio

Lanraplenib, is a next-generation SYK inhibitor that has previously been studied as a potential treatment for autoimmune diseases. In preclinical studies, Lanraplenib was shown to have anti-leukemic activity against NPM1-mutated and FLT3-mutated AML samples. Lanraplenib, is being developed for the treatment of patients with relapsed/refractory FLT3-mutated AML and patients newly diagnosed with NPM1-mutated and/orFLT3-mutated AML who are older than 75 years old or are not eligible for intensive induction chemotherapy.

Learn more about Relapsed/Refractory Acute Myeloid Leukemia Drugs opportunities in our groundbreaking Relapsed/Refractory Acute Myeloid Leukemia Research and development projects @ Relapsed/Refractory Acute Myeloid Leukemia Unmet Needs

Relapsed/refractory acute myeloid leukemia (AML) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

Relapsed/Refractory Acute Myeloid Leukemia Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

Discover the latest advancements in Relapsed/Refractory Acute Myeloid Leukemia Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Relapsed/Refractory Acute Myeloid Leukemia Market Drivers and Barriers, and Future Perspectives

Relapsed/Refractory Acute Myeloid Leukemia Market Drivers

  • Rising incidence of Acute Myeloid Leukemia, advancements in pharmacology and molecular biology to promote drug development, rising geriatric population are some of the important factors that are fueling the Relapsed/Refractory Acute Myeloid Leukemia Market.

Relapsed/Refractory Acute Myeloid Leukemia Market Barriers

  • However, high cost associated with the management of AML, side effects associated with the AML treatment and other factors are creating obstacles in the Relapsed/Refractory Acute Myeloid Leukemia Market growth.

Scope of the Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report

  • Coverage- Global
  • Relapsed/Refractory Acute Myeloid Leukemia Companies- Ascentage Pharma, Cullinan Oncology, Kronos Bio, Maxinovel Pharmaceuticals, AB Science, CicloMed, Karyopharm Therapeutics, Antengene Corporation, GlycoMimetics, Servier, Novartis, ImmunoGen, and others.
  • Relapsed/Refractory Acute Myeloid Leukemia Therapies- UCART 123, FHD-286, AB8939, ONC201, Sarclisa, TCB008, Keytruda, Uproleselan, Crenolanib, and others.
  • Relapsed/Refractory Acute Myeloid Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Relapsed/Refractory Acute Myeloid Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Relapsed/Refractory Acute Myeloid Leukemia Pipeline on our website @ Relapsed/Refractory Acute Myeloid Leukemia Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Relapsed/refractory acute myeloid leukemia (AML): Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Relapsed/refractory acute myeloid leukemia (AML)– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name : Company name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase I/II)
  11. APG-2575: Ascentage Pharma
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. CLN 049: Cullinan Oncology
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name : Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Relapsed/refractory acute myeloid leukemia (AML) Key Companies
  21. Relapsed/refractory acute myeloid leukemia (AML) Key Products
  22. Relapsed/refractory acute myeloid leukemia (AML)- Unmet Needs
  23. Relapsed/refractory acute myeloid leukemia (AML)- Market Drivers and Barriers
  24. Relapsed/refractory acute myeloid leukemia (AML)- Future Perspectives and Conclusion
  25. Relapsed/refractory acute myeloid leukemia (AML) Analyst Views
  26. Relapsed/refractory acute myeloid leukemia (AML) Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories